{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020846","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.922401+00:00","generated_at":"2026-06-15T04:41:32.774228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa Q1 net loss $32M; cash $237M; MRT-2359 data on track for H2 2023","bullets":["Net loss $32M in Q1 2023 vs $23.9M in Q1 2022; R&D expenses $26.8M vs $17.9M.","Cash, equivalents, and marketable securities $237M as of March 31, 2023, down from $268.1M at Dec 31, 2022; runway into 2025.","Phase 1/2 trial of MRT-2359 in MYC-driven solid tumors on track for initial data in H2 2023.","VAV1 program expects to declare a development candidate in Q2 2023.","Appointed Jan Skvarka, Ph.D., MBA, to the Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020846","json":"https://secwatch.observer/filing/0000950170-23-020846.json","markdown":"https://secwatch.observer/filing/0000950170-23-020846.md","text":"https://secwatch.observer/filing/0000950170-23-020846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023020846/0000950170-23-020846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023020846/glue-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:41:32.774228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f7a79be16f1d6282120dfaf2f63b0c09364a86f","claim":"Monte Rosa Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $32 million.","evidence_excerpt":"On May 11, 2023, Monte Rosa Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023020846/0000950170-23-020846-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $32 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}